

# Clinical trials of bococizumab

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>bococizumab vs placebo</b>			
<b>SPIRE-1</b> <i>ongoing</i> [NCT01975376] n=NA follow-up:	Bococizumab versus placebo	high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C $\geq$ 70 mg/dL (1.8 mmol/L) and $<$ 100 mg/dL (2.6 mmol/L) or non-HDL-C $\geq$ 100 mg /dl (2.6 mmol/L) and $<$ 130 mg/dL (3.4 mmol/L).	double-blind
<b>SPIRE-2</b> <i>ongoing</i> [NCT01975389] n=NA follow-up:	bococizumab versus Placebo	high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C $\geq$ 100 mg/dL (2.6 mmol/L) or non-HDL-C $\geq$ 130 mg/dL (3.4 mmol/L).	double-blind
<b>SPIRE-FH</b> <i>ongoing</i> [NCT01968980] n=NA follow-up:	-	subjects with heterozygous familial hypercholesterolemia receiving highly effective statins	double-blind US
<b>SPIRE-HR</b> <i>ongoing</i> [NCT01968954] n=NA follow-up:	Bococizumab versus Placebo	subjects with high cholesterol receiving highly effective statins	double-blind US
<b>SPIRE-LDL</b> <i>ongoing</i> [NCT01968967] n=NA follow-up:	-	subjects with high cholesterol receiving highly effective statins	double-blind US
<b>SPIRE-LL</b> <i>ongoing</i> [NCT02100514] n=NA follow-up:	-	subjects with hyperlipidemia receiving background statin therapy	double-blind US

continued...

Trial	Treatments	Patients	Trials design and methods
<b>SPiRE-SI</b> <i>ongoing</i> [NCT02135029] n=NA follow-up:	Bococizumab versus Placebo	-	double-blind

More details and results :

- PCSK9 Inhibitors for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q599>

## References

### **SPiRE-1, 0:**

ongoing trial NCT01975376

### **SPiRE-2, 0:**

ongoing trial NCT01975389

### **SPiRE-FH, 0:**

ongoing trial NCT01968980

### **SPiRE-HR, 0:**

ongoing trial NCT01968954

### **SPiRE-LDL, 0:**

ongoing trial NCT01968967

### **SPiRE-LL, 0:**

ongoing trial NCT02100514

### **SPiRE-SI, 0:**

ongoing trial NCT02135029

Entry terms: bococizumab,